“No” is a word they’ve heard too often.

Alexion is a global biopharmaceutical company focused on serving patients with severe and life-threatening rare diseases. Patients with these devastating diseases often have no effective treatment options, and they and their families suffer with little hope. Our goal is to develop and deliver therapies that will dramatically transform their lives.

From Our Leadership

As we fulfil our mission of serving patients with severe and life-threatening rare diseases, Alexion has built its European presence to meet the needs of patients locally. Today, our European operations serve patients in more than 30 countries. In addition, several of Alexion’s key global functions are based in Europe, including our EMEA headquarters in Switzerland and our global supply chain and quality operations in Ireland. We also have a global government affairs team in Brussels, a new research and development centre in Paris, and country operations throughout the region. Alexion’s talented and driven employees are dedicated to providing life-transforming treatments to patients with severe and life-threatening rare diseases for which there are few, if any, effective treatment options. We invite you to learn more about what we do.

— Christophe Bourdon
Senior Vice President, EMEA




Kanuma Wins 2016 German Prix Galien Award

Kanuma® (sebelipase alfa) has been awarded the prestigious 2016 German Prix Galien Award in the Orphan Product category, recognising the innovation behind this novel enzyme replacement therapy for patients living with lysosomal acid lipase deficiency (LAL-D). The Prix Galien Award honours outstanding achievement in the development of new medicines, and is widely considered the highest accolade for pharmaceutical research and development.


Alexion Employees in Europe Join Colleagues Around the World for Global Day of Service

On September 23, 2016, more than 1,500 Alexion employees volunteered in their local communities as part of the Company’s first Global Day of Service. The event helped inspire and connect em¬ployees with a common purpose and brought hands-on support to some of the most pressing needs in our local neighborhoods. Activities in Europe included beautifying parks, schools, and gardens, working with hospitalized individuals and those with special needs, and more. Read our press release to learn more.


Alexion Receives International Investor Award 2016

Alexion is honored to have received a 2016 International Investor Award from the Greater Paris Investment Agency (Paris-Ile de France Capitale Economique) for its significant investment and growth in Paris, France. Alexion first established its presence in France in 2005 and, in 2015, opened a new Research and Development Center in Paris – its first European research hub for rare and severe diseases. Alexion’s R&D Center Paris, which is located at the campus of the Necker Hospital at the Imagine Institute, focuses on discovery research activities in the fields of cell and molecular biology, genomics, and immunogenicity. Read the press release and learn more about Alexion’s R&D Center.


Alexion Announces Additional Investment in Ireland

Alexion has announced an additional €100 million investment in its Athlone operations in Ireland, which will result in the creation of 50 additional jobs. The investment will see the construction of a new biologics manufacturing facility at the site. Read the media statement.


EMEA Headquarters
Alexion Pharma GmbH

Giessh├╝belstrasse 30
8045 Z├╝rich, Switzerland
  • +41 44  457 40 00
  • +41 44 457 40 01